Is talquetamab-tgvs a targeted drug?

Talquetamab is a targeted immunotherapy drug designed to treat cancers such as multiple myeloma. Unlike traditional chemotherapy drugs, tarquinatumumab enhances the immune system's anti-tumor effects by specifically targeting a receptor on the surface of cancer cells. Specifically, taquitumab targets GPRC5D, a receptor highly expressed on multiple myeloma cells. By binding to the T-cell receptor CD3, Taquitumumab can guide T cells to tumor cells and activate immune responses, thereby effectively clearing tumor cells.

Taquitumab is a type of immune checkpoint inhibitor and bispecific antibody. Its mechanism of action works by mobilizing the body's immune system to fight cancer, rather than directly killing cancer cells through traditional chemical means. Therefore, it can be considered a"targeted immunotherapy drug." This makes Taquitumab more selective and less side-effects than traditional therapeutic drugs in the treatment of tumors such as multiple myeloma.

As a targeted drug, the targeting nature of Taquinutumab allows it to precisely act on cancer cells during the treatment process, minimizing damage to normal cells. This is also a significant advantage of it as a treatment option. Compared with traditional treatments such as chemotherapy, targeted drugs usually have milder side effects and are more effective.

To sum up, Tacistumumab is a targeted immunotherapy drug that mainly activates the function ofT cells and targets the GPRC5D receptor on the surface of cancer cells, thereby enhancing the anti-tumor ability of the immune system. This gives it great potential in treating cancers such as multiple myeloma.

Reference materials:https://www.talveyhcp.com/